Intellia Therapeutics (NTLA) Assets Average (2016 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Assets Average data on file, last reported at $800.5 million in Q1 2026.

• Assets Average for Q1 2026 came in at $800.5 million, down 26.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $800.5 million (down 26.47% YoY), and the FY2025 annual result was $1.0 billion, down 18.41% from the prior year.
• Assets Average eased to $800.5 million in Q1 2026 per NTLA's latest filing, from $883.7 million in the prior quarter.
• Over five years, Assets Average peaked at $1.5 billion in Q1 2023 and troughed at $800.5 million in Q1 2026.
• A 5-year average of $1.2 billion and a median of $1.2 billion in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2026: Assets Average soared 79.24% in 2022, then retreated 26.47% in 2026.
• A 5-year view of Assets Average shows it stood at $1.3 billion in 2022, then declined by 2.31% to $1.3 billion in 2023, then slipped by 7.07% to $1.2 billion in 2024, then slipped by 25.25% to $883.7 million in 2025, then slipped by 9.42% to $800.5 million in 2026.
• Business Quant data shows NTLA's Assets Average at $800.5 million in Q1 2026, $883.7 million in Q4 2025, and $912.1 million in Q3 2025.